Abbott Laboratories: Q2 Surprise and Forecast Upgrade Ignite Stock Rally!
Reading Time: 2 minutes
The US healthcare company Abbott Laboratories exceeded analysts' expectations for revenue ($12.593 billion) and profit in the second quarter. The increase of the annual forecast for adjusted earnings per share to $5.45 to $5.60 demonstrates operational acceleration. The trigger for the strong accumulation under high trading volume is the recovery dynamics in medical technology. Abbott Laboratories is one of the most broadly positioned players in the global healthcare sector, operating in the segments of medical devices, diagnostics, established...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
